Idorsia IDRSF Stock
Idorsia Price Chart
Idorsia IDRSF Financial and Trading Overview
| Idorsia stock price | 2.44 USD |
| Previous Close | 8.8 USD |
| Open | 8.8 USD |
| Bid | 0 USD x 0 |
| Ask | 0 USD x 0 |
| Day's Range | 8.8 - 8.8 USD |
| 52 Week Range | 8.5 - 19.14 USD |
| Volume | 43.2K USD |
| Avg. Volume | 1.49K USD |
| Market Cap | 1.58B USD |
| Beta (5Y Monthly) | 0.559386 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.31 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
IDRSF Valuation Measures
| Enterprise Value | 2.57B USD |
| Trailing P/E | N/A |
| Forward P/E | N/A |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 14.00408 |
| Price/Book (mrq) | N/A |
| Enterprise Value/Revenue | 22.761 |
| Enterprise Value/EBITDA | -3.266 |
Trading Information
Idorsia Stock Price History
| Beta (5Y Monthly) | 0.559386 |
| 52-Week Change | -35.48% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 19.14 USD |
| 52 Week Low | 8.5 USD |
| 50-Day Moving Average | 9.55 USD |
| 200-Day Moving Average | 13.1 USD |
IDRSF Share Statistics
| Avg. Volume (3 month) | 1.49K USD |
| Avg. Daily Volume (10-Days) | 6.92K USD |
| Shares Outstanding | 177.92M |
| Float | 109.65M |
| Short Ratio | N/A |
| % Held by Insiders | 36.03% |
| % Held by Institutions | 23.21% |
| Shares Short | N/A |
| Short % of Float | N/A |
| Short % of Shares Outstanding | N/A |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | -713.90% |
| Gross Margin | -243.89% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -51.55% |
| Return on Equity (ttm) | N/A |
Income Statement
| Revenue (ttm) | 112.94M USD |
| Revenue Per Share (ttm) | 0.64 USD |
| Quarterly Revenue Growth (yoy) | 305.69% |
| Gross Profit (ttm) | -292495000 USD |
| EBITDA | -787105984 USD |
| Net Income Avi to Common (ttm) | -842524032 USD |
| Diluted EPS (ttm) | -5.14 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 220.02M USD |
| Total Cash Per Share (mrq) | 1.24 USD |
| Total Debt (mrq) | 1.23B USD |
| Total Debt/Equity (mrq) | N/A |
| Current Ratio (mrq) | 2.259 |
| Book Value Per Share (mrq) | -4.835 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -871225984 USD |
| Levered Free Cash Flow (ttm) | -560545984 USD |
Profile of Idorsia
| Country | United States |
| State | N/A |
| City | Allschwil |
| Address | Hegenheimermattweg 91 |
| ZIP | 4123 |
| Phone | 41 58 844 10 10 |
| Website | https://www.idorsia.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | N/A |
Idorsia Ltd, a biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for unmet medical needs in Switzerland. The company has a clinical development pipeline that cover various therapeutic areas, including CNS, cardiovascular, and immunological disorders, as well as orphan diseases. Its products include PIVLAZ (clazosentan), available in 150 mg, is indicated for the prevention of cerebral vasospasm, vasospasm-related cerebral infarction, and cerebral ischemic symptoms after aneurysmal subarachnoid hemorrhage securing; and QUVIVIQ (daridorexant), available in 25 and 50 mg, for the treatment of adult patients with insomnia. Idorsia Ltd has a collaboration agreement with Janssen Biotech Inc. to jointly develop and commercialize aprocitentan and its derivative compounds or products; license agreement with Mochida Pharmaceutical for the supply, co-development, and comarketing of daridorexant; and Hoffman-La Roche Inc. to develop and market compounds in the field of cancer immunotherapy. It also has a collaboration with Neurocrine Biosciences, Inc. to develop and commercialize ACT-709478, which is in Phase II clinical trial for the treatment of epilepsy. The company was incorporated in 2017 and is headquartered in Allschwil, Switzerland.
Q&A For Idorsia Stock
What is a current IDRSF stock price?
Idorsia IDRSF stock price today per share is 2.44 USD.
How to purchase Idorsia stock?
You can buy IDRSF shares on the OTC Markets OTCPK exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Idorsia?
The stock symbol or ticker of Idorsia is IDRSF.
Which industry does the Idorsia company belong to?
The Idorsia industry is Biotechnology.
How many shares does Idorsia have in circulation?
The max supply of Idorsia shares is 180.91M.
What is Idorsia Price to Earnings Ratio (PE Ratio)?
Idorsia PE Ratio is now.
What was Idorsia earnings per share over the trailing 12 months (TTM)?
Idorsia EPS is -2.31 USD over the trailing 12 months.
Which sector does the Idorsia company belong to?
The Idorsia sector is Healthcare.